B of A Securities Downgrades FibroGen to Underperform, Lowers Price Target to $2
Portfolio Pulse from richadhand@benzinga.com
B of A Securities analyst Jason Gerberry has downgraded FibroGen (NASDAQ:FGEN) from Neutral to Underperform and lowered the price target from $4 to $2.
August 08, 2023 | 12:49 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
FibroGen has been downgraded from Neutral to Underperform by B of A Securities, with a lowered price target from $4 to $2.
The downgrade from B of A Securities is a negative signal for FibroGen. The lowered price target from $4 to $2 indicates a bearish outlook for the stock, which could lead to a decrease in its price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100